Cargando…
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
Breast cancer is the leading cause of cancer related deaths in women worldwide and is classified into subtypes based on the cancer’s receptor status. Of these subtypes, those expressing the human epidermal growth factor receptor 2 (HER2) receptor were traditionally associated with poor prognosis. Se...
Autores principales: | Coté, Damien, Eustace, Alex, Toomey, Sinead, Cremona, Mattia, Milewska, Malgorzata, Furney, Simon, Carr, Aoife, Fay, Joanna, Kay, Elaine, Kennedy, Susan, Crown, John, Hennessy, Bryan, Madden, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071997/ https://www.ncbi.nlm.nih.gov/pubmed/30071039 http://dx.doi.org/10.1371/journal.pone.0200996 |
Ejemplares similares
-
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016) -
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018) -
Frequency, impact and a preclinical study of novel
ERBB gene family mutations in HER2-positive breast
cancer
por: Elster, Naomi, et al.
Publicado: (2018) -
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017) -
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)